{"cik":1540171,"taxonomy":"us-gaap","tag":"EarningsPerShareBasic","label":"Earnings Per Share, Basic","description":"The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.","entityName":"Avalyn Pharma Inc.","units":{"USD/shares":[{"start":"2025-01-01","end":"2025-03-31","val":-63.24,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":-52.83,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2025-04-01","end":"2025-06-30","val":-17.63,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2025Q2"},{"start":"2025-01-01","end":"2025-09-30","val":-69.29,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12"},{"start":"2025-07-01","end":"2025-09-30","val":-20.34,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2025Q3"},{"start":"2026-01-01","end":"2026-03-31","val":-21.83,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":-3.6,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2026-04-01","end":"2026-06-30","val":-0.98,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2"},{"start":"2026-01-01","end":"2026-09-30","val":-3.39,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12"},{"start":"2026-07-01","end":"2026-09-30","val":-0.67,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2026Q3"}]}}